title: Octreotide treatment of acromegaly. A randomized, multicenter study.
abstract: OBJECTIVE
  To determine the effects of the somatostatin analog, octreotide acetate, in patients with acromegaly.
  
  
  METHODS
  Double-blind, randomized trial.
  
  
  METHODS
  Fourteen university-affiliated medical centers.
  
  
  METHODS
  One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
  
  
  METHODS
  Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks. Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  
  
  RESULTS
  After 2 weeks of treatment, a single 100-micrograms injection reduced mean serum growth hormone (GH) to 30% of the pretreatment concentration within 2 hours. The integrated mean GH level was reduced over 8 hours from 39 +/- 11 micrograms/L to 9 +/- 2 micrograms/L (P less than 0.001). Mean plasma insulin-like growth factor-1 (IGF-1) was reduced from 5100 +/- 400 U/L to 2400 +/- 400 U/L (P less than 0.001). After 6 months, the mean GH was reduced from 39 +/- 13 to 15 +/- 4 micrograms/L by 300 micrograms of octreotide and from 29 +/- 5 micrograms/L to 9 +/- 2 micrograms/L by 750 micrograms of octreotide daily. The mean IGF-1 concentration was suppressed to 2100 +/- 300 and 2500 +/- 400 U/L after 300 and 750 micrograms octreotide, respectively. Integrated mean GH levels were reduced to < 5 micrograms/L in 53% (95% CI, 39% to 67%) and 49% (CI, 35% to 63%), and IGF-1 levels were normal in 68% (CI, 54% to 82%) and 55% (CI, 40% to 70%) of patients receiving low- and high-dose octreotide, respectively. A substantial decrease in headache, amount of perspiration, joint pain, and finger circumference occurred in two thirds of the patients. The pituitary size was reduced in 19% (CI, 5% to 33%) and 37% (CI, 22% to 52%) of patients receiving 6 months of low- and high-dose octreotide, respectively. Ten percent and 13% of patients in each treatment group developed transient diarrhea; 10% and 14%, biliary sludge; and 6% and 18%, cholelithiasis, respectively.
  
  
  CONCLUSIONS
  Octreotide effectively decreased GH and IGF-1 concentrations in 53% and 68% of patients, respectively. The higher dose resulted in increased frequency of tumor shrinkage but added no biochemical or clinical benefit.
authors.affiliation: Wellesley Hospital, Toronto, Ontario, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Ezzat
authors.forename: P J
authors.initials: PJ
authors.lastname: Snyder
authors.forename: W F
authors.initials: WF
authors.lastname: Young
authors.forename: L D
authors.initials: LD
authors.lastname: Boyajy
authors.forename: C
authors.initials: C
authors.lastname: Newman
authors.forename: A
authors.initials: A
authors.lastname: Klibanski
authors.forename: M E
authors.initials: ME
authors.lastname: Molitch
authors.forename: A E
authors.initials: AE
authors.lastname: Boyd
authors.forename: L
authors.initials: L
authors.lastname: Sheeler
authors.forename: D M
authors.initials: DM
authors.lastname: Cook
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000209:etiology; D000236:Adenoma / Q000150:complications / Q000188:drug therapy; D000328:Adult; D000595:Amino Acid Sequence; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000187:drug effects; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy; D011446:Prospective Studies
chemical_list: D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide